EPA Moves to Rescind Biden-Era Ethylene Oxide Limits, Reigniting Debate Over Safety and Supply Chain
A new proposal from the U.S. Environmental Protection Agency (EPA) is reshaping the regulatory landscape for medical device sterilization - potentially reversing key elements of a 2024 rule aimed at reducing emissions of ethylene oxide (EtO), a widely used but carcinogenic chemical.
The move marks a significant policy shift under the Trump administration, highlighting an ongoing tension between public health protections and the operational realities of the healthcare supply chain.
What the EPA Is Proposing
In March 2026, the EPA announced plans to reconsider - and potentially rescind - portions of the Biden-era National Emission Standards for Hazardous Air Pollutants (NESHAP) governing commercial sterilization facilities.
The 2024 rule had required stringent emissions controls and monitoring, targeting roughly 90 sterilization facilities nationwide and aiming to cut EtO emissions by about 90%.
Under the new proposal, the EPA argues those requirements were overly burdensome, legally questionable, and potentially disruptive to the domestic supply of sterilized medical products.
Agency officials emphasize that ethylene oxide remains indispensable: it is used to sterilize approximately 50% of all medical devices in the U.S. - roughly 20 billion products annually.
EtO is essential for sterilizing complex, heat-sensitive medical equipment, including pacemakers, catheters, syringes, surgical kits, and implants. However, the EPA classified EtO as a human carcinogen in 2016, with long-term exposure linked to leukemia, breast cancer, lymphoma, and other serious health effects, raising environmental justice concerns tied to chronic exposure.
Industry and Supply Chain Pressures
The EPA’s reconsideration reflects mounting pressure from industry stakeholders and federal agencies, including the FDA, who have warned that strict emissions limits could disrupt sterilization capacity and create shortages of critical medical devices.
According to the agency, the Biden-era rule prompted concerns about facility closures and forced the creation of exemptions to avoid supply disruptions.
The proposed rollback is positioned as a way to “ensure a strong domestic supply chain” for essential medical equipment while continuing to evaluate updated scientific data on EtO exposure and toxicity.
A Broader Policy Signal
The EPA’s move underscores a broader challenge for the life sciences sector: balancing innovation, safety, and supply chain resilience in areas where alternatives are still emerging. While research into non-EtO sterilization methods and advanced decontamination technologies continues, few options currently match the scale, compatibility, and efficiency required for many medical devices.
What Comes Next
The EPA is accepting public comments on the proposal and is expected to finalize the rule within the next year. For stakeholders across the medical device ecosystem - from manufacturers and sterilization providers to regulators and public health advocates - the outcome will have far-reaching implications.
